Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 2/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384312 | 0.94 | EGFR (0.39) | EGFRCYP1A2AGTR1LMNAGCGR | |
| SCHEMBL4378145 | 0.89 | EGFR (0.40) | EGFRGCGRUSP7CAPN1 | |
| SCHEMBL4382860 | 0.86 | EGFR (0.34) | EGFRGCGRCAPN1 | |
| SCHEMBL4390311 | 0.85 | HMGCR (0.39) | EGFRCYP1A2AGTR1LMNAGCGR | |
| SCHEMBL4394187 | 0.85 | CYP1A2 (0.39) | EGFRCYP1A2AGTR1LMNAGCGR | |
| SCHEMBL4384285 | 0.84 | EGFR (0.35) | EGFRGCGRCAPN1 | |
| SCHEMBL4395298 | 0.83 | CYP1A2 (0.38) | EGFRCYP1A2AGTR1LMNAGCGR | |
| SCHEMBL4381132 | 0.83 | EGFR (0.39) | EGFRGCGRUSP7 | |
| SCHEMBL4381984 | 0.83 | EGFR (0.41) | EGFRGCGRUSP7 | |
| SCHEMBL4392049 | 0.82 | EGFR (0.36) | EGFRGCGRUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | EGFR 624/4885CYP1A2 1290/4885AGTR1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.